As of May 24
| +0.20 / +2.81%|
The 7 analysts offering 12-month price forecasts for Aldeyra Therapeutics Inc have a median target of 28.00, with a high estimate of 38.00 and a low estimate of 20.00. The median estimate represents a +281.99% increase from the last price of 7.33.
The current consensus among 7 polled investment analysts is to Buy stock in Aldeyra Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.